| 56S1 Stock | | | EUR 184.25 0.95 0.52% |
Chairman
Dr. Joachim Kreuzburg has served as Chairman of the Board and Chief Executive Officer, Chairman of the Executive Committee of Sartorius Stedim Biotech SA since June 29, 2007. He is also Member of the Company Remuneration Committee. In addition to his duties at the Company, Dr. Kreuzburg held several other mandates, including Vice Chairman of the Supervisory Board of Sartorius Stedim Biotech GmbH and Member of the Board of Directors of Sartorius Mechatronics Japan K.K., among others. He started his career working as a Scientific Assistant at the Research Institute on Solar Energy of Lower Saxony from 1992 to 1995. Subsequently, he was Scientific Assistant at the department of Economics of Hannover University until 1999. He then joined Sartorius AG as Director of Finance and Investors Relations on May 1, 1999. In November 2002, he was appointed Member of the Management Board of Sartorius AG and Director of Finance, Administration and Investors Relations. Between May 2003 and November 2005, Dr. Kreuzburg served as Spokesperson of the Management Board of Sartorius AG. Since November 11, 2005, he was Chairman of the Management Board of Sartorius AG since 2007.
| Age | 58 |
| Tenure | 17 years |
| Professional Marks | Ph.D |
| Phone | 33 4 42 84 56 00 |
| Web | https://www.sartorius.com |
Kreuzburg holds a degree in Mechanical Engineering from Gottfried Wilhelm Leibniz Universitaet Hannover, a Doctorate degree in Political Science and a Doctorate degree in Economics.
Sartorius Stedim Management Efficiency
The company has return on total asset
(ROA) of
0.1548 % which means that it generated a profit of $0.1548 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.4143 %, meaning that it generated $0.4143 on every $100 dollars invested by stockholders. Sartorius Stedim's management efficiency ratios could be used to measure how well Sartorius Stedim manages its routine affairs as well as how well it operates its assets and liabilities.
Sartorius Stedim Biotech has accumulated 1.02
B in total debt with debt to equity ratio
(D/E) of 0.39, which is about average as compared to similar companies. Sartorius Stedim Biotech has a current ratio of 1.47, which is within standard range for the sector. Debt can assist Sartorius Stedim until it has trouble settling it off, either with new capital or with free cash flow. So, Sartorius Stedim's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sartorius Stedim Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sartorius to invest in growth at high rates of return. When we think about Sartorius Stedim's use of debt, we should always consider it together with cash and equity.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. SARTOR STED operates under Medical Instruments Supplies classification in Germany and is traded on Frankfurt Stock Exchange. It employs 8200 people. Sartorius Stedim Biotech (56S1) is traded on Frankfurt Exchange in Germany and employs 11,934 people.
Management Performance
Sartorius Stedim Biotech Leadership Team
Elected by the shareholders, the Sartorius Stedim's board of directors comprises two types of representatives: Sartorius Stedim inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sartorius. The board's role is to monitor Sartorius Stedim's management team and ensure that shareholders' interests are well served. Sartorius Stedim's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sartorius Stedim's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rene Faber, Non-Executive Director | |
| AnneMarie Graffin, Non-Executive Independent Director | |
| Petra Kirchhoff, Vice President of Corporate Communications and Investor Relations | |
| Henri Riey, Non-Executive Independent Director | |
| Pascale Boissel, Non-Executive Independent Director | |
| Olivier Guitard, Head BPS | |
| Joachim Kreuzburg, Chairman of the Board and Chief Executive Officer, Chairman of the Executive Committee | |
| Susan Dexter, Non-Executive Independent Director | |
| Heiko Imhl, VP Relations | |
| Amelie Buton, Non-Executive Director, Employee Representative | |
| Lothar Kappich, Non-Executive Director | |
| Benedikt Orzelek, Investor Relations Contact | |
| John Mackay, Sales Marketing | |
Sartorius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sartorius Stedim a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Sartorius Stock
Sartorius Stedim financial ratios help investors to determine whether Sartorius Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.